Lenz Therapeutics (NASDAQ:LENZ) reported second quarter 2025 results on July 30, revealing $5.0 million in GAAP revenue from licensing milestones, significantly surpassing analyst expectations. Despite a deeper net loss due to increased spending, the company made strides in its commercial plans ahead of an important FDA decision for its lead product, LNZ100, aimed at treating presbyopia.
Want More Context? 🔎
World Kinect (WKC) Q2 EPS Jumps 23%
World Kinect (NYSE:WKC) reported Q2 2025 results on July 31, revealing adjusted EPS of $0.59, surpassing the $0.48 forecast, while GAAP revenue of $9.04 billion fell short of the $9.32 billion expectation and declined 18% year-over-year. The quarter included $405 million in impairment and restructuring charges due to a strategic overhaul, particularly in the Land segment, despite strong performance in Aviation. Want More Context? 🔎
Read more